Calamos Advisors
BCRX icon

Calamos Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Calamos Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-103,359
Closed -$1.68M – 1161
2022
Q1 		$1.68M Buy
+103,359
New +$1.66M 0.01% 943

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Calamos Advisors's BCRX Position: Q2 2022 in Review

Calamos Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 103,359 shares — an estimated $1.68M sold.

Calamos Advisors first reported a position in BCRX in Q1 2022 and held it in 1 quarter. The position peaked at $1.68M in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Calamos Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Calamos Advisors sold 103,359 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $1.68M.
  • Calamos Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Calamos Advisors's BioCryst Pharmaceuticals position peaked at $1.68M in Q1 2022.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Calamos Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.